{"news_desk": "SundayBusiness", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"contributor": "Jack Begg and Christina Capecchi contributed reporting.", "original": "By KATIE THOMAS", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}]}, "abstract": "Deeply flawed study of anti-psychotic drug Seroquel XR, which initially offered new hope for treating borderline personality disorder, reveals how conflicts of interest among academics and universities can result in messy research; study was financed by AstraZeneca, which manufactures Seroquel, and was overseen by Dr S Charles Schulz, head of psychiatry at Univ of Minnesota with strong ties to pharmaceutical industry.", "type_of_material": "News", "word_count": "2456", "lead_paragraph": "A study of the drug Seroquel XR for patients with borderline personality disorder exposes the tangled mess of interests for academics and universities involved in clinical trials.", "pub_date": "2015-04-19T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "A Drug Trial&#8217;s Frayed Promise", "print_headline": "A Drug Trial\u2019s Frayed Promise"}, "snippet": "A study of the drug Seroquel XR for patients with borderline personality disorder exposes the tangled mess of interests for academics and universities involved in clinical trials.", "multimedia": [{"height": 126, "url": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbWide-v2.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbWide-v2.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 419, "url": "images/2015/04/19/business/19DRUGTRIALJP1/19-DRUGTRIAL-JP1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "419", "xlarge": "images/2015/04/19/business/19DRUGTRIALJP1/19-DRUGTRIAL-JP1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbStandard-v2.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbStandard-v2.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/04/19/business/seroquel-xr-drug-trial-frayed-promise.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Mental Health and Disorders", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "AstraZeneca PLC", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Schulz, S Charles", "name": "persons"}, {"rank": "5", "is_major": "N", "value": "Research", "name": "subject"}, {"rank": "6", "is_major": "Y", "value": "Colleges and Universities", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Clinical Trials", "name": "subject"}, {"rank": "8", "is_major": "Y", "value": "University of Minnesota", "name": "organizations"}], "blog": [], "_id": "5531430b38f0d86ab80c21ea", "source": "The New York Times"}